4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Molecular Tools for Nucleic Acid Manipulation for Biological Intervention (MMBio)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,
MMbio will bridge the classically separate disciplines of Chemistry and Biology by assembling leading experts from academia and non-academic partners (industry, technology transfer & science communication) to bring about systems designed to interfere therapeutically with gene expression in living cells. Expertise in nucleic acid synthesis, its molecular recognition and chemical reactivity is combi ...
Voir le projet
13
Participants partenaires
TERMINÉ
European Gram Negative Antibacterial Engine (ENABLE)
Date du début: 1 févr. 2014, Date de fin: 31 janv. 2020,
...idable consequence of antibiotic use and therefore new, effective antibacterials will always be needed and once developed should be used carefully, avoiding the overuse which can drive resistance. Despite the recognized need for new antimicrobials for clinical use, the reality is that only two new classes of antibiotics have been brought to market in the last 30 years and many drug developers hav ...
Voir le projet
42
Participants partenaires
TERMINÉ
Innovative Nanoformulation of Antimicrobial Peptides to Treat Bacterial Infectious Diseases (FORMAMP)
Date du début: 1 déc. 2013, Date de fin: 30 nov. 2017,
...eginning of the last century. Antimicrobial peptides (AMPs) have a huge potential as new therapeutics against infectious diseases as they are less prone to induce resistance due to their fast and non-specific mechanism of action. The aim of FORMAMP is to explore a number of innovative formulation and delivery strategies based on nanotechnology in order to improve the efficiency and stability of AM ...
Voir le projet
18
Participants partenaires
TERMINÉ
Preclinical development of drugs and drug delivery technology for the treatment of inherited photoreceptor degeneration (DRUGSFORD)
Date du début: 1 sept. 2012, Date de fin: 31 août 2016,
...reventing photoreceptor damage in preclinical disease models. Towards this goal, two SMEs have teamed up with three academic research groups focused on retinal degeneration: the German company BIOLOG specializes on development of cyclic nucleotide based drugs targeting PKG, CNGC, and GC; the Dutch company to-BBB develops systems to deliver drugs across the blood brain/retinal barrier (BBB, BRB, re ...
Voir le projet